Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter SARS-CoV-2 Nucleocapsid Antikörper

SARS-CoV-2 N Reaktivität: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV) ELISA, IF Wirt: Kaninchen Chimeric CR3018 (03-018) unconjugated Recombinant Antibody
Produktnummer ABIN6953059
  • Target Alle SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) Antikörper anzeigen
    SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
    Antikörpertyp
    Recombinant Antibody
    Reaktivität
    • 59
    • 10
    • 5
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV)
    Wirt
    • 31
    • 15
    • 15
    • 4
    • 1
    • 1
    Kaninchen
    Klonalität
    • 52
    • 10
    • 4
    Chimeric
    Konjugat
    • 49
    • 9
    • 5
    • 2
    • 1
    Dieser SARS-CoV-2 Nucleocapsid Antikörper ist unkonjugiert
    Applikation
    • 56
    • 26
    • 11
    • 6
    • 6
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    ELISA, Immunofluorescence (IF)
    Spezifität
    This antibody binds the amino acid residues between 11-19 of the N protein of the SARS CoV as well as SARS-CoV-2 (COVID-19) nucleocapsid protein.
    Produktmerkmale

    OriginalSpeciesName: Human

    OriginalFormat: IgG1

    Aufreinigung
    Protein A affinity purified
    Immunogen
    The original antibody was generated by cloning the variable regions of the scFvs selected from phage display libraries into separate vectors for IgG1 heavy-chain and light-chain expression. The harvested supernatents were then purified on protein A columns. The original immunogen was the whole irradiated virion.
    Klon
    CR3018 (03-018)
    Isotyp
    IgG kappa
    Top Product
    Discover our top product SARS-CoV-2 N Primärantikörper
  • Applikationshinweise
    This antibody is recommended for detection of SARS CoV2 protein N (nucleoprotein). This antibody binds both the nucleocapsid protein of the SARS-CoV and SARS CoV-2 (2019-nCoV). Initial characterization of the antibody for binding to 2019-nCoV was done using ELISA. This antibody shows potential to be used for development of diagnostic assays. Various isotype versions of the antibody namely human IgG1, IgG3, IgM, IgA and the less common IgG2 and IgG4 are available for the investigation of their role in response to SARS CoV2. Competitive ELISA of this antibody with CR3009 suggests that both these antibodies bind different epitopes of the N protein of SARS CoV. Thus, a combination of these two antibodies is suggested for virus capture assays. Immunofluorescence staining was used to demonstrate binding of CR3018 to SARS-CoV infected Vero cells.

    Competitive ELISA of both anti-nucleocapsid antibodies suggests that they bind different, non-overlapping epitopes of the N protein of SARS-CoV. Thus, a combination of these two antibodies is suggested for virus capture assays. Clone CR3018 binds the amino acid residues between 11-19 of the N protein of SARS-CoV, while clone CR3009 binds a non-linear/conformational epitope of the N protein of SARS-CoV, both of which are sufficiently conserved to permit binding of these antibodies to SARS-CoV-2.
    Kommentare

    This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 mg/mL
    Buffer
    PBS with 0.02 % Proclin 300.
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Gaynor, Vaysburd, Harman, Albecka, Jeffrey, Beswick, Papa, Chen, Mallery, McGuinness, Van Rietschoten, Stanway, Brear, Lulla, Ciazynska, Chang, Sharp, Neary, Box, Herriott, Kijak, Tatham, Bentley et al.: "Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2. ..." in: Nature communications, Vol. 14, Issue 1, pp. 3583, (2023) (PubMed).

    Ramm, Dondapati, Trinh, Wenzel, Walter, Zemella, Kubick: "The Potential of Eukaryotic Cell-Free Systems as a Rapid Response to Novel Zoonotic Pathogens: Analysis of SARS-CoV-2 Viral Proteins." in: Frontiers in bioengineering and biotechnology, Vol. 10, pp. 896751, (2022) (PubMed).

    van den Brink, Ter Meulen, Cox, Jongeneelen, Thijsse, Throsby, Marissen, Rood, Bakker, Gelderblom, Martina, Osterhaus, Preiser, Doerr, de Kruif, Goudsmit: "Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus." in: Journal of virology, Vol. 79, Issue 3, pp. 1635-44, (2005) (PubMed).

  • Target
    SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
    Andere Bezeichnung
    SARS-CoV-2 Nucleocapsid Protein (SARS-CoV-2 N Produkte)
    Synonyme
    nucleocapsid phosphoprotein antikoerper, N antikoerper
    Substanzklasse
    Viral Protein
    Hintergrund
    NP, NC, Protein N, Nucleocapsid protein, SARS-CoV Protein N, SARS-CoV Nucleocapsid protein, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV
    UniProt
    P0DTC9, P59595
Sie sind hier:
Kundenservice